Secondary Progressive Multiple Sclerosis

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020.

Patients with secondary progressive MS on disease-modifying treatments often are clinically misclassified as having relapsing-remitting MS, most likely because they are not reassigned categorically until after conversion has occurred.

A blood test may be able to identify patients with multiple sclerosis who are more likely to have worsening disability, according to research published in Neurology, the medical journal of the American Academy of Neurology.